Future of the USA's Medicare examined in the post-McClellan era

24 September 2006

The abrupt resignation of Mark McClellan as Administrator for the Center for medicare and Medicaid Services (CMS), which comes into effect next month (Marketletter September 11), coincides with surveys examining the success of the Medicare Part D prescription drug benefit for America's senior citizens, as well as the debate on what improvement, if any, should be made to the program.

By joining a think-tank, believed to be the free-market leaning American Enterprise Institute, Mr McClellan will have the freedom to express his views on how the Medicare modernization process has fared and what direction it should take from here. Robert Samuelson, writing an opinion column in the Washington Post newspaper, described the Medicare program as the "monster of the future," which will consume most of the increases in federal health care spending from 2000 to 2030.

Mr Samuelson's prognosis is gloomy: "now, uncontrolled health spending will dominate the federal budget and pose ugly choices: raise taxes sharply; gut other programs; and run ever-larger - and more dangerous - deficits."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight